Yarrow Bioscience, Inc. last reported quarterly results on Jul 28, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $97,000 (+40.6% year over year) and diluted EPS of -$3.51. It usually reports 28–38 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–38 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Jul 28, 2026
28 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
+40.6%
|
-3
+47.7%
|
-3.51
+47.8%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
—
|
—
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-65.2%
|
-6
+38.8%
|
-6.73
-2959.1%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
+106.1%
|
-9
-37.8%
|
-0.20
-33.3%
|
|
Mar 6, 2025
65 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
+10.5%
|
-12
-94.3%
|
-0.28
-41.3%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
+6.1%
|
-12
-84.6%
|
-0.29
+85.6%
|
|
Aug 14, 2024
45 days after quarter end
|
Q2 FY2024
ended Jun 30, 2024
|
0
+46.7%
|
-9
+6.5%
|
-0.22
+92.9%
|
|
May 9, 2024
39 days after quarter end
|
Q1 FY2024
ended Mar 31, 2024
|
0
-1.0%
|
-6
-11.2%
|
-0.15
+91.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- YARW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1566044
- Former names
- VYNE Therapeutics Inc. (until Jul 24, 2026); Menlo Therapeutics Inc. (until Sep 2, 2020); Menlo Therapeutics, Inc. (until Jan 31, 2018); Tigercat Pharma, Inc. (until Jan 7, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.